A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trials

2011 ◽  
Vol 85 (1) ◽  
pp. 9-28 ◽  
Author(s):  
Kathy Musa-Veloso ◽  
Theresa H. Poon ◽  
Julie Ann Elliot ◽  
Catherine Chung
2016 ◽  
Vol 116 (8) ◽  
pp. 1369-1382 ◽  
Author(s):  
Hoang V. T. Ho ◽  
John L. Sievenpiper ◽  
Andreea Zurbau ◽  
Sonia Blanco Mejia ◽  
Elena Jovanovski ◽  
...  

AbstractOats are a rich source ofβ-glucan, a viscous, soluble fibre recognised for its cholesterol-lowering properties, and are associated with reduced risk of CVD. Our objective was to conduct a systematic review and meta-analysis of randomised-controlled trials (RCT) investigating the cholesterol-lowering potential of oatβ-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for the risk reduction of CVD. MEDLINE, Embase, CINAHL and Cochrane CENTRAL were searched. We included RCT of ≥3 weeks of follow-up, assessing the effect of diets enriched with oatβ-glucan compared with controlled diets on LDL-cholesterol, non-HDL-cholesterol or apoB. Two independent reviewers extracted data and assessed study quality and risk of bias. Data were pooled using the generic inverse-variance method with random effects models and expressed as mean differences with 95 % CI. Heterogeneity was assessed by the Cochran’sQstatistic and quantified by theI2-statistic. In total, fifty-eight trials (n3974) were included. A median dose of 3·5 g/d of oatβ-glucan significantly lowered LDL-cholesterol (−0·19; 95 % CI −0·23, −0·14 mmol/l,P<0·00001), non-HDL-cholesterol (−0·20; 95 % CI −0·26, −0·15 mmol/l,P<0·00001) and apoB (−0·03; 95 % CI −0·05, −0·02 g/l,P<0·0001) compared with control interventions. There was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol (I2=79 %) and non-HDL-cholesterol (I2=99 %). Pooled analyses showed that oatβ-glucan has a lowering effect on LDL-cholesterol, non-HDL-cholesterol and apoB. Inclusion of oat-containing foods may be a strategy for achieving targets in CVD reduction.


2014 ◽  
Vol 112 (2) ◽  
pp. 214-219 ◽  
Author(s):  
Rouyanne T. Ras ◽  
Johanna M. Geleijnse ◽  
Elke A. Trautwein

Phytosterols (PS, comprising plant sterols and plant stanols) have been proven to lower LDL-cholesterol concentrations. The dose–response relationship for this effect has been evaluated in several meta-analyses by calculating averages for different dose ranges or by applying continuous dose–response functions. Both approaches have advantages and disadvantages. So far, the calculation of averages for different dose ranges has not been done for plant sterols and stanols separately. The objective of the present meta-analysis was to investigate the combined and separate effects of plant sterols and stanols when classified into different dose ranges. Studies were searched and selected based on predefined criteria. Relevant data were extracted. Average LDL-cholesterol effects were calculated when studies were categorised by dose, according to random-effects models while using the variance as weighing factor. This was done for plant sterols and stanols combined and separately. In total, 124 studies (201 strata) were included. Plant sterols and stanols were administered in 129 and fifty-nine strata, respectively; the remaining used a mix of both. The average PS dose was 2·1 (range 0·2–9·0) g/d. PS intakes of 0·6–3·3 g/d were found to gradually reduce LDL-cholesterol concentrations by, on average, 6–12 %. When plant sterols and stanols were analysed separately, clear and comparable dose–response relationships were observed. Studies carried out with PS doses exceeding 4 g/d were not pooled, as these were scarce and scattered across a wide range of doses. In conclusion, the LDL-cholesterol-lowering effect of both plant sterols and stanols continues to increase up to intakes of approximately 3 g/d to an average effect of 12 %.


2019 ◽  
Vol 149 (6) ◽  
pp. 968-981 ◽  
Author(s):  
Sonia Blanco Mejia ◽  
Mark Messina ◽  
Siying S Li ◽  
Effie Viguiliouk ◽  
Laura Chiavaroli ◽  
...  

ABSTRACT Background Certain plant foods (nuts and soy protein) and food components (viscous fibers and plant sterols) have been permitted by the FDA to carry a heart health claim based on their cholesterol-lowering ability. The FDA is currently considering revoking the heart health claim for soy protein due to a perceived lack of consistent LDL cholesterol reduction in randomized controlled trials. Objective We performed a meta-analysis of the 46 controlled trials on which the FDA will base its decision to revoke the heart health claim for soy protein. Methods We included the 46 trials on adult men and women, with baseline circulating LDL cholesterol concentrations ranging from 110 to 201 mg/dL, as identified by the FDA, that studied the effects of soy protein on LDL cholesterol and total cholesterol (TC) compared with non-soy protein. Two independent reviewers extracted relevant data. Data were pooled by the generic inverse variance method with a random effects model and expressed as mean differences with 95% CI. Heterogeneity was assessed and quantified. Results Of the 46 trials identified by the FDA, 43 provided data for meta-analyses. Of these, 41 provided data for LDL cholesterol, and all 43 provided data for TC. Soy protein at a median dose of 25 g/d during a median follow-up of 6 wk decreased LDL cholesterol by 4.76 mg/dL (95% CI: −6.71, −2.80 mg/dL, P < 0.0001; I2 = 55%, P < 0.0001) and decreased TC by 6.41 mg/dL (95% CI: −9.30, −3.52 mg/dL, P < 0.0001; I2 = 74%, P < 0.0001) compared with non-soy protein controls. There was no dose–response effect or evidence of publication bias for either outcome. Inspection of the individual trial estimates indicated most trials (∼75%) showed a reduction in LDL cholesterol (range: −0.77 to −58.60 mg/dL), although only a minority of these were individually statistically significant. Conclusions Soy protein significantly reduced LDL cholesterol by approximately 3–4% in adults. Our data support the advice given to the general public internationally to increase plant protein intake. This trial was registered at clinicaltrials.gov as NCT03468127.


2000 ◽  
Vol 71 (2) ◽  
pp. 472-479 ◽  
Author(s):  
James W Anderson ◽  
Lisa D Allgood ◽  
Ann Lawrence ◽  
Linda A Altringer ◽  
George R Jerdack ◽  
...  

2016 ◽  
Vol 7 (9) ◽  
pp. 3973-3980 ◽  
Author(s):  
Wen-Jun Cao ◽  
Shi-Yi Ou ◽  
Wei-Feng Lin ◽  
Chuan-He Tang

Phytosterols are a group of plant sterols with well-recognized LDL-cholesterol lowering effects. The water solubility and bioaccessibility of these compounds can be greatly improved by encapsulation within food protein-based nanoparticles.


Sign in / Sign up

Export Citation Format

Share Document